- SEK1.36bn
- SEK1.05bn
Brief: Flerie Receives Approval For Merger With Lipum
Brief: Flerie To Divest Holdings In Limited Partnership Segment
Brief: Flerie, Lipum Have Agreed On Merger Plan
Brief: Flerie's Xintela's XSTEM Shows Safety And Efficacy 24 Months Post-Treatment
Brief: Swedish Companies Registration Office Permits Implementation of Flerie, Toleranzia's M&A
Brief: Flerie H1 Net Asset Value Down At SEK 4,121 Million
Brief: Flerie Holds 43.59% Of Shares In Nanologica
Brief: Nanologica Board Recommends Not To Accept Cash Offer Made By Flerie Invest
Brief: Flerie Portfolio Company Receives First U.S. Order
Brief: Flerie Invest Announces Mandatory Cash Offer To Shareholders Of Nanologica
Brief: Flerie, Toleranzia General Meetings Approve Merger Plan
Brief: Flerie Jan-March NAV SEK 3,947 Million
Brief: Flerie's Lipum Presents Final Results From Phase I Trial Of Sol-116
Brief: Flerie Sells Toleranzia Shares To Long-Term Flerie Investors
Brief: Flerie's Unit Provell Pharmaceuticals Files For Bankruptcy Under Chapter 7 In U.S.
Brief: Flerie's NAV Per Share At SEK 50.56
Brief: Toleranzia Recommends Shareholders To Vote For Merger With Flerie
Brief: Flerie And Toleranzia Agree On Merger Plan To Take Toleranzia Private
Brief: Flerie Divests Shares In A3P Biomedical For SEK 71.3 Mlm